MARK SAMSON: Open Payments
NPI 1386637189 · DUBLIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$646 in 39 payments from 11 companies in 2025. Trend: 2023 $280 · 2024 $341 · 2025 $646
Food & beverage: $646
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $144 |
| PFIZER INC. | 7 | $120 |
| Astellas Pharma US Inc | 5 | $85 |
| ABBVIE INC. | 3 | $67 |
| Philips North America LLC | 2 | $54 |
| Seqirus USA Inc | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Abbott Laboratories | 2 | $30 |
| Lundbeck LLC | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: OTEZLA, Veozah, NURTEC ODT, ECC Solutions, AIRSUPRA, PREVNAR 20, QULIPTA, UBRELVY.
Industry payments across GA — which companies pay providers there.
